Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17075155 | 0.77 | PARP1 (0.39) | PARP1HTR2AHTR2CHTR2B | |
| SCHEMBL17075237 | 0.74 | HTR2C (0.58) | HTR2AHTR2CHTR2B | |
| SCHEMBL17075249 | 0.74 | HTR2C (0.58) | HTR2AHTR2CHTR2B | |
| SCHEMBL17075247 | 0.74 | HTR2C (0.58) | HTR2AHTR2CHTR2B | |
| SCHEMBL8266332 | 0.71 | HTR2C (0.59) | PARP1HTR2AHTR2CHTR2B | |
| SCHEMBL6202369 | 0.69 | HTR2C (0.53) | PARP1HTR2CHTR2BPARP10PARP11 | |
| SCHEMBL15522951 | 0.68 | PARP1 (0.36) | PARP1PARP10PARP11 | |
| SCHEMBL30185581 | 0.67 | PARP3 (0.50) | PARP1HTR2AHTR2CHTR2BPARP10 | |
| SCHEMBL15522686 | 0.64 | MEN1 (0.42) | PARP1HTR2AHTR2CHTR2BPARP10 | |
| Boric Acid SCHEMBL29099586 | 0.62 | PARP3 (0.49) | PARP1HTR2AHTR2CHTR2BPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116874-B1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL | ABBVIE DEUTSCHLAND (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-20170112851-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-04-27 | — | — | US | disclosed |
| US-9540376-B2 | Hexahydrodiazepinoquinolines carrying a substituted alkyl radical | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-01-10 | — | — | US | disclosed |
| US-20150259346-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112851-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL | HTR2C, HTR2A, HTR3C | PARP1 1117/4885HTR2A 2/4885HTR2C 1/4885 |
| US-20150259346-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL | HTR2C, HTR2A, HTR3C | PARP1 1117/4885HTR2A 2/4885HTR2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.